Naftifine hydrochloride (brand names include Exoderil and Naftin) is an allylamine antifungal drug for the topical treatment of tinea pedis, tinea cruris, and tinea corporis (topical fungal infections).
Clinical data | |
---|---|
Trade names | Exoderil, Naftin |
AHFS/Drugs.com | Monograph |
MedlinePlus | a688020 |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H21N |
Molar mass | 287.406 g·mol−1 |
(what is this?) (verify) |
Naftifine was invented at the Sandoz Research Institute in Vienna, Austria. It was the first successful antifungal medication of the allylamine class.[1]
Naftifine has triple action: antifungal, antibacterial, and anti-inflammatory. Its fungistatic activity is believed to be based on inhibition of the squalene-2,3-epoxidase enzyme, which in turn results in the shortage of ergosterol required for the formation of fungal cell membranes. With some fungal species, there is also fungicidal activity from a resulting accumulation of squalenes, leading to damage of the fungal cell membranes, including at the endoplasmatic reticulum.[1][2][3] Naftifine shows mostly fungicidal activity toward dermatophytes and molds, and mostly fungistatic activity toward yeasts. It is also effective as an antibacterial agent in treating pyoderma. [citation needed]
Naftifine is almost completely metabolized in the human body, with a half-life of 2–3 days.[3] The metabolites do not have antifungal activity, and are excreted within urine and feces.[4]
References
edit- ^ a b Mühlbacher JM (1991). "Naftifine: a topical allylamine antifungal agent". Clinics in Dermatology. 9 (4): 479–85. doi:10.1016/0738-081x(91)90076-w. PMID 1822408.
- ^ Robertson DB, Maibach HI (2009). "Dermatologic Pharmacology.". In Katzung BG, Masters SB, Trevor AJ (eds.). Basic and Clinical Pharmacology (11th ed.). New York: McGraw Hill Medical. ISBN 978-0-07-160406-2.
- ^ a b Naftifine Hydrochloride. Micromedex DRUGDEX Drug Point (Report). 18 February 2010..
- ^ Sebela Pharmaceuticals Inc. (April 2018). "NAFTIN®- naftifine hydrochloride gel" (PDF). www.accessdata.fda.gov. Retrieved 2022-07-03.